Loading
MECOM (Histone-lysine N-methyltransferase MECOM) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Endometrial cancer and 5 more.
Functions as a transcriptional regulator binding to DNA sequences in the promoter region of target genes and regulating positively or negatively their expression. Oncogene which plays a role in development, cell proliferation and differentiation. May also play a role in apoptosis through regulation of the JNK and TGF-beta signalling.
CIViC holds 5 clinical evidence items and 1 assertion across 3 variants. Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes affected pathway 0.26, literature 0.99, genetic association 0.63, somatic mutation 0.80, animal model 0.50). IntOGen calls it a driver in 6 cohorts (3 activating, 3 loss-of-function), covering Invasive Breast Carcinoma, Melanoma, Prostate Adenocarcinoma, Endometrial Carcinoma.
In plain words · MECOM (Histone-lysine N-methyltransferase MECOM) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Endometrial cancer and 5 more.
MECOM (Histone-lysine N-methyltransferase MECOM) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Endometrial cancer and 5 more.
Functions as a transcriptional regulator binding to DNA sequences in the promoter region of target genes and regulating positively or negatively their expression.
No product in this corpus aims at MECOM yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance) and a fusion partner (UniProt records a translocation), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA MECOM: RNA tissue enhanced (stomach 1 69 nTPM); high antibody staining in 42 normal tissues; highest cancer staining ovarian cancer (10 of 11 high). Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Prostate cancer, Endometrial cancer, Skin cancer (all types), Lung cancer (all types), Ovarian cancer, Leukaemia); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q03112; CIViC gene MECOM; IntOGen MECOM; Human Protein Atlas MECOM tissue; Open Targets ENSG00000085276 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Morishita et al, Oncogene, 1990, "Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts". Source.
Sources: HGNC HGNC:3498 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q03112 (protein name, function text, keywords and locations (REST API)); CIViC gene MECOM (5 evidence items, 1 assertions, 3 variants; diseases: Acute Myeloid Leukaemia With MECOM Rearrangement, Acute Myeloid Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000085276 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: prostate cancer 0.54, ovarian cancer 0.51, melanoma 0.61, skin cancer 0.57, breast cancer 0.59, lung cancer 0.54 (GraphQL API, CC0)); IntOGen MECOM (driver in 6 cohorts (Act 3, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Functions as a transcriptional regulator binding to DNA sequences in the promoter region of target genes and regulating positively or negatively their expression. Oncogene which plays a role in development, cell proliferation and differentiation. May also play a role in apoptosis through regulation of the JNK and TGF-beta signalling. Involved in haematopoiesis. Displays histone methyltransferase activity and monomethylates 'Lys-9' of histone H3 (H3K9me1). Probably catalyses the monomethylation of free histone H3 in the cytoplasm which is then transported to the nucleus and incorporated into nucleosomes where SUV39H methyltransferases use it as a substrate to catalyse histone H3 'Lys-9' trimethylation. Location: Nucleus; Nucleus speckle; Cytoplasm (UniProt). Locus 3q26.2 (HGNC).
RNA: tissue enhanced (stomach 1 69 nTPM), detected in many normal tissues.
Medium: Liver, Parathyroid gland.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"MECOM" OR ABSTRACT:"MECOM" OR TITLE:"MDS1 and EVI1 complex locus" OR ABSTRACT:"MDS1 and EVI1 complex locus" OR TITLE:"Histone-lysine N-methyltransferase MECOM" OR ABSTRACT:"Histone-lysine N-methyltransferase MECOM" OR TITLE:"MDS1-EVI1" OR ABSTRACT:"MDS1-EVI1" OR TITLE:"PRDM3" OR ABSTRACT:"PRDM3" OR TITLE:"KMT8E" OR ABSTRACT:"KMT8E") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MECOM, not a curated reading list.